⁶⁸Ga-PSMA PET auf dem Weg zur neuen Standardbildgebung bei Prostatakarzinom?

Zusammenfassung

Dieser Artikel beschreibt den aktuellen Stand der Bildgebung mit ⁶⁸Ga-PSMA PET beim Prostatakarzinom. Sowohl bei der lokalen Tumordetektion als auch beim Primär- und Rezidivstaging können hervorragende Spezifitäten bei gleichzeitig höherer Sensitivität im Vergleich zu den bisherigen, konventionellen Bildgebungen erzielt werden. Somit wird die ⁶⁸Ga-PSMA PET voraussichtlich in Zukunft eine noch größere Rolle in der Diagnostik des Prostatakarzinoms einnehmen und weitere Verbreitung erfahren.

Abstract

This article describes the current knowledge in prostate cancer imaging with ⁶⁸Ga-PSMA PET, which achieves excellent specificities and higher sensitivities compared with standard imaging for local tumour detection as well as primary and recurrence staging. Therefore, ⁶⁸Ga-PSMA PET will probably play an increasing role for the diagnostic investigation of prostate cancer and will be more widely used in the future.

Schlüsselwörter

PSMA - Prostatakarzinom - PET - Staging - Rezidiv

Key words

PSMA - prostate cancer - PET - staging - recurrence

• Literatur

• 1 Torre LA, Bray F, Siegel RL et al. Global Cancer Statistics, 2012. Ca – a Cancer Journal for Clinicians 2015; 65: 87-108
• 2 Haberland J, Bertz J, Wolf U et al. German cancer statistics 2004. BMC Cancer 2010; 10: 10
• 3 Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung. Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Im Internet http://www.awmf.org/uploads/tx_szleitlinien/043-022OLl_S3_Prostatakarzinom_2014-12.pdf 2014
• 4 Heck MM, Souvatzoglou M, Retz M et al. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and C-11 choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging 2014; 41: 694-701
• 5 Evangelista L, Guttilla A, Zattoni F et al. Utility of Choline Positron Emission Tomography/Computed Tomography for Lymph Node Involvement Identification in Intermediate- to High-risk Prostate Cancer: A Systematic Literature Review and Meta-analysis. Eur Urol 2013; 63: 1040-1048
• 6 Maurer T, Eiber M, Schwaiger M et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 2016.
• 7 Eder M, Schaefer M, Bauder-Wuest U et al. Ga-68-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjug Chem 2012; 23: 688-697
• 8 Mease RC, Foss CA, Pomper MG. PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen. Curr Top Med Chem 2013; 13: 951-962
• 9 Afshar-Oromieh A, Haberkorn U, Eder M et al. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. European journal of nuclear medicine and molecular imaging 2012; 39: 1085-1086
• 10 Eiber M, Weirich G, Holzapfel K et al. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol. 2016
• 11 Maurer T, Gschwend JE, Rauscher I et al. Diagnostic Efficacy of Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging in Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2015
• 12 Maurer T, Beer AJ, Wester HJ et al. Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?. International journal of urology: official journal of the Japanese Urological Association 2014; 21: 1286-1288
• 13 Eiber M, Nekolla SG, Maurer T et al. (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdominal imaging 2015; 40: 1769-1771
• 14 Afshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a Ga-68-labelled PSMA ligand and F-18-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20
• 15 European Association of Urology. Guidelines on Prostate Cancer. Im Internet http://uroweb.org/guideline/prostate-cancer/ 2016
• 16 Valerio M, Donaldson I, Emberton M et al. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. Eur Urol 2015; 68: 8-19
• 17 Souvatzoglou M, Eiber M, Martinez-Moeller A et al. PET/MR in prostate cancer: technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging 2013; 40: S79-S88
• 18 Souvatzoglou M, Eiber M, Takei T et al. Comparison of integrated whole-body C-11 choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40: 1486-1499
• 19 Zettinig O, Shah A, Hennersperger C et al. Multimodal image-guided prostate fusion biopsy based on automatic deformable registration. Int J Comput Assist Radiol Surg 2015; 10: 1997-2007
• 20 Budaus L, Leyh-Bannurah SR, Salomon G et al. Initial Experience of Ga-68-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016; 69: 393-396
• 21 Pyka T, Okamoto S, Dahlbender M et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. J Nucl Med Mol Imaging, accepted 2016;
• 22 Pfister D, Bolla M, Briganti A et al. Early Salvage Radiotherapy Following Radical Prostatectomy. Eur Urol 2014; 65: 1034-1043
• 23 Rouviere O, Vitry T, Lyonnet D. Imaging of prostate cancer local recurrences: why and how?. Eur Radiol 2010; 20: 1254-1266
• 24 Afshar-Oromieh A, Avtzi E, Giesel FL et al. The diagnostic value of PET/CT imaging with the Ga-68-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209
• 25 Eiber M, Maurer T, Souvatzoglou M et al. Evaluation of Hybrid Ga-68-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668-674
• 26 Krause BJ, Souvatzoglou M, Tuncel M et al. The detection rate of C-11 Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 18-23
• 27 Maurer T, Weirich G, Schottelius M et al. Prostate-specific Membrane Antigen-radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. Eur Urol 2015; 68: 530-534
• 28 Maurer T, Eiber M, Wirtz M et al. 438 PSMA-radioguided surgery for recurrent prostate cancer – mid-term follow-up and novel developments. European Urology Supplements 2016; 15: e438
• 29 Sweat SD, Pacelli A, Murphy GP et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52: 637-640
• 30 Baum RP, Kulkarni HR, Schuchardt C et al. Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med 2016;
• 31 Haberkorn U, Eder M, Kopka K et al. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin Cancer Res 2016; 22: 9-15
• 32 Ahmadzadehfar H, Rahbar K, Kurpig S et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI research 2015; 5: 114-114
• 33 Weineisen M, Schottelius M, Simecek J et al. Ga-68- and Lu-177-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med 2015; 56: 1169-1176
• 34 Heck MM, Retz M, D'Alessandria C et al. Systemic Radioligand Therapy with Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. J Urol 2016;
• 35 Delker A, Fendler WP, Kratochwil C et al. Dosimetry for Lu-177-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 42-51
• 36 Kratochwil C, Giesel FL, Eder M et al. Lu-177 Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 987-988